Nassif, Michael E.

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2022) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 951

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial

Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 618

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 424

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 245

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial

Kosiborod, M. N., Esterline, R., Furtado, R. H. M., Oscarsson, J., Gasparyan, S. B., Koch, G. G., Martinez, F., Mukhtar, O., Verma, S., Chopra, V., et al. (2021) · The Lancet Diabetes & Endocrinology

COVID-19 Clinical Research StudiesDiabetes Treatment and Management

Cited by 243

Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications

Gunawan, F., Nassif, M. E., Partridge, C., Ahmad, T., Kosiborod, M., & Inzucchi, S. E. (2020) · Cardiovascular Endocrinology & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 28